Samar Mohanty
President & CSO, Nanoscope Therapeutics
Samar Mohanty is listed as President & CSO, Nanoscope Therapeutics. Samar is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Samar. Is this you? Claim this profile.
About
Dedicated to transforming scientific discoveries into life-changing therapies, Dr. Samarendra Mohanty co-founded Nanoscope Therapeutics and serves as president and chief scientific officer. With over 25 years of experience in biomedical sciences, Dr. Mohanty has co-founded several biotech and medical device companies focused on developing and commercializing innovative diagnostics and therapeutic technologies. His mission-driven work bridges cutting-edge science and patient impact, with a focus on neurological and ophthalmic disorders. Dr. Mohanty holds an M.Tech in Applied Optics from IIT Delhi and a PhD in (Bio)Physics from IISc Bangalore. He has held senior academic and research positions worldwide and is Principal Investigator for major NIH-funded projects. With over 200 international patents and publications in top journals like Nature, Dr. Mohanty remains a leader in biomedical innovation. He continues to innovate and serve on the Boards of many biotech companies.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel: Building a sustainable commercial future for rare and nano-rare advanced therapies Speaker · 19 January 2027
- Session 3: How to ensure the long-term future of advanced therapies for rare, ultra-rare and nano-rare diseases? Speaker · 19 January 2027
- Fireside Chat: Designing early clinical trials that generate meaningful proof of concept Speaker · 20 January 2027
- How do you plan and execute successful overseas IIT in the APAC and Australian regions? Speaker · 20 January 2027
- Plenary: Plotting a course to sustainable future success for the cell & gene therapy industry Speaker · 20 January 2027
- Roundtable discussion: The global picture Speaker · 20 January 2027
- Session 5: Innovation in early clinical trial design and execution: how to streamline the pathway to rapid clinical proof of concept while avoiding the pitfalls? Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Samar at events on B2DB.
- Gina Jiang Managing Director · Hong Kong Institute of Biotechnology 2 shared sessions
- Mary Hames Board Member · CURE NDD 2 shared sessions
- Peter He Co-Founder & Chief Scientific Officer · OriCell Therapeutics 2 shared sessions
- Yoshiaki Maruyama Director, Office of Cellular and Tissue-based Products · Pharmaceuticals and Medical Devices Agency (PMDA), Japan 2 shared sessions
- Zoya Gluzman-Poltorak CEO and Co-Founder · Forta Bio 2 shared sessions
- Sven Kili Partner · Saisei Ventures 1 shared session
- Cédric Cleyrat Executive Director, Head of Cell Therapy BioEngineering & Technology Innovation · Bristol Myers Squibb 1 shared session
- Jacob Rosenberg VP Clinical Operations · Tr1X 1 shared session
- Kirsten Vonde Principal Consultant · Granzer Regulatory Consulting & Services GmbH 1 shared session
- Miguel Forte CEO, Kiji Therapeutics and Immediate Past President, International Society of Cell and Gene Therapy · Kiji Therapeutics 1 shared session
- Nelly Viseux VP Cell Therapies Development, Manufacturing Supply & Quality · Regeneron Pharmaceuticals 1 shared session
- Steven Oh Director, Office of Cellular Therapy and Human Tissue, Office of Therapeutic Products, CBER · US Food & Drug Administration 1 shared session